NovoCure
NVCR
327 hedge funds and large institutions have $9.95B invested in NovoCure in 2021 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 100 increasing their positions, 133 reducing their positions, and 64 closing their positions.
222% more call options, than puts
Call options by funds: $254M | Put options by funds: $78.8M
0.61% more ownership
Funds ownership: 72.92% → 73.53% (+0.61%)
8% less funds holding
Funds holding: 356 → 327 (-29)
23% less capital invested
Capital invested by funds: $12.9B → $9.95B (-$2.9B)
25% less repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 133
38% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 64
50% less funds holding in top 10
Funds holding in top 10: 8 → 4 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$141M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$136M |
| 3 |
BlackRock
New York
|
+$99.4M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$95.4M |
| 5 |
Two Sigma Investments
New York
|
+$54.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$85.3M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$77.2M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$48.3M |
| 4 |
DCP
Darsana Capital Partners
New York
|
-$39.5M |
| 5 |
Goldman Sachs
New York
|
-$30.7M |
NVCR Hedge Fund Activity: Q1 2021 in Review
327 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q1 2021, worth a combined $9.95B — down 23% from $12.9B a quarter earlier.
Sellers outnumbered buyers: 64 funds closed out of NVCR and 40 opened new positions — a net loss of 24 holders — while 133 trimmed existing stakes and 100 added.
The largest buyer was Capital World Investors, adding an estimated $141M. The largest seller was Fidelity Investments, cutting an estimated $85.3M.
- 327 institutional investors held NovoCure (NVCR) as of Q1 2021, down from 356 in Q4 2020.
- Funds reported $9.95B of NovoCure stock for Q1 2021, down 23% quarter-over-quarter.
- 40 funds opened new NovoCure positions in Q1 2021 and 64 closed out, a net change of -24 holders.
- The largest NovoCure buyer in Q1 2021 was Capital World Investors, an estimated $141M added.
- The largest NovoCure seller in Q1 2021 was Fidelity Investments, an estimated $85.3M sold.
Based on aggregated 13F filings for Q1 2021.